Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Belantamab Mafodotinblmf

Research Leaders

5 sponsors active, led by GSK

Related Conditions

Often studied with 19 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Phase 1 (1)
Phase 1/2 (3)

Trial Status

Completed2
Unknown1
Not Yet Recruiting1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT03820817Phase 1Completed

Rifaximin in Patients With Monoclonal Gammopathy

NCT06559579CompletedPrimary

Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)

NCT05280275Phase 1/2Unknown

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

NCT05573802Phase 1/2Recruiting

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

NCT05581875Phase 1/2Not Yet Recruiting

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Showing all 5 trials

Research Network

Common Treatments

  • Belantamab Mafodotinblmf3
  • Dexamethasone3
  • Daratumumab2
  • Lenalidomide2
  • Nirogacestat1

Active Sponsors

  • GSK3
  • Hellenic Society of Hematology3
  • Emory University1
  • University Hospital, Brest1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Paraproteinemias3
  • Blood Protein Disorders3
  • Multiple Myeloma3
  • Corneal Disease3
  • Neoplasms3

Activity Timeline